Schulhoff & Co. Inc. Has $971,000 Holdings in Merck & Co., Inc. $MRK

Schulhoff & Co. Inc. grew its holdings in Merck & Co., Inc. (NYSE:MRK) by 2.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,263 shares of the company’s stock after purchasing an additional 300 shares during the period. Schulhoff & Co. Inc.’s holdings in Merck & Co., Inc. were worth $971,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Barnes Dennig Private Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the first quarter valued at approximately $27,000. Legend Financial Advisors Inc. acquired a new position in Merck & Co., Inc. during the second quarter worth $25,000. CBIZ Investment Advisory Services LLC increased its holdings in Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after buying an additional 221 shares during the last quarter. MorganRosel Wealth Management LLC acquired a new position in Merck & Co., Inc. during the first quarter worth $36,000. Finally, Fiduciary Wealth Partners LLC acquired a new position in Merck & Co., Inc. during the first quarter worth $48,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MRK has been the topic of a number of recent analyst reports. Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They set a “neutral” rating and a $95.00 target price on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Wells Fargo & Company reduced their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Morgan Stanley reduced their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. Finally, Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Hold” and an average target price of $104.33.

Merck & Co., Inc. Trading Up 1.5%

Shares of Merck & Co., Inc. stock opened at $87.61 on Wednesday. The firm has a 50-day moving average of $84.18 and a 200-day moving average of $81.39. The stock has a market cap of $218.83 billion, a PE ratio of 13.50, a PEG ratio of 0.95 and a beta of 0.37. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $107.36. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. The company had revenue of $15.81 billion during the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.